Reaction

Carbon Dioxide Increased reporting signals

Last recalculated 2026-09-14T18:28:35.993900+00:00 · 1,348 reports · 51 co-occurring drugs

As of the last recalculation, Carbon Dioxide Increased appears in 1,348 FAERS reports alongside 51 co-occurring drug terms. The strongest observed disproportionality signal is 0XYGEN (PRR 25.9).

Important: FAERS is a spontaneous, voluntary, unverified reporting system. PRR and ROR identify reporting patterns for investigation; they are not incidence rates and do not establish causation.

Drug	Co-reports	PRR	ROR
0Xygen	78	25.9	25.9
Oxygen	78	25.9	25.9
Theophylline	17	23.1	23.1
Theophylline Anhydrous	17	21.4	21.5
Sevoflurane	11	20.6	20.6
Sildenafil	57	15.8	15.8
Ipratropium Bromide	34	15.1	15.1
Bosentan	45	14.2	14.2
Ciclesonide	12	13.7	13.7
Macitentan	58	13.5	13.5
Sildenafil Powder,	30	13.3	13.3
Fluticasone Furoate And Vilanterol Trifenatate	30	13.1	13.2
Ado-Trastuzumab Emtansine	7	12.9	12.9
Treprostinil	93	12.2	12.2
Tiotropium Bromide	98	11.8	11.8
Sildenafil Citrate	89	11.5	11.5
Bumetanide	19	11.3	11.3
Metolazone	8	11.0	11.1
Ambrisentan	84	11.0	11.0
Asfotase Alfa	7	10.8	10.8
Riociguat	22	10.6	10.6
Rocuronium Bromide	8	10.5	10.5
Mepolizumab	33	10.5	10.5
Dornase Alfa	13	10.3	10.3
Amikacin	11	10.0	10.0
Fluticasone Propionate And Salmeterol Xinafoate	38	10.0	10.0
Tobramycin	15	9.7	9.7
Tiotropium Bromide Inhalation Spray	7	9.7	9.7
Selexipag	16	9.7	9.7
Instalax Polyethylene Glycol 3350	7	8.8	8.8
Polyethylene Glycol 400	7	8.6	8.6
Benzonatate	9	8.5	8.5
Guanfacine	4	7.9	7.9
Ivacaftor	4	7.8	7.8
Budesonide, Glycopyrrolate, And Formoterol Fumarate	5	7.4	7.4
Pancrelipase	18	7.3	7.3
Fluticasone Furoate, Umeclidinium Bromide And Vilanterol Trifenatate	19	7.2	7.2
Testosterone Cypionate	4	6.9	6.9
Umeclidinium	4	6.9	6.9
Tadalafil	42	6.7	6.7
Nintedanib	12	6.0	6.0
Lumacaftor And Ivacaftor	3	5.4	5.4
Pirfenidone	14	5.4	5.4
Tolvaptan	5	5.3	5.3
Umeclidinium Bromide And Vilanterol Trifenatate	5	4.6	4.6
Ranolazine	3	4.4	4.4
Benralizumab	5	3.9	3.9
Elexacaftor, Tezacaftor, And Ivacaftor	3	3.7	3.7
Romosozumab-Aqqg	3	3.4	3.4
Palivizumab	3	3.0	3.0
Lifitegrast	3	2.8	2.8

Related reactions

Data source: openFDA FAERS. See the OpenPV methodology and limitations.